What is the recommended acute management for methamphetamine intoxication and the long‑term treatment options for methamphetamine use disorder?

Methamphetamine Management

For acute methamphetamine intoxication, prioritize symptom-directed treatment with benzodiazepines for agitation and cardiovascular complications, while for long-term methamphetamine use disorder, contingency management represents the current standard of care and should be offered as first-line treatment 1.

Acute Methamphetamine Intoxication Management

Immediate Assessment and Stabilization

Acute methamphetamine toxicity presents distinctly from opioid overdoses, characterized by anxiety (43%), heart pounding (34%), and rapid heart rate (33%), rather than loss of consciousness 2. Life-threatening complications require immediate recognition and appropriate level of care 1.

Symptom-Directed Treatment Approach

Agitation Control:

• Benzodiazepines are the primary intervention for acute agitation 3, 4
• Atypical antipsychotics may be used if benzodiazepines are insufficient 4
• Avoid physical restraints when possible; prioritize chemical sedation

Cardiovascular Complications:

• Monitor for hypertension, tachycardia, and arrhythmias
• Control severe hypertension with appropriate antihypertensives
• Avoid beta-blockers alone (risk of unopposed alpha-adrenergic stimulation)

Neurological Complications:

• Screen for intracranial hemorrhage in patients with severe headache or altered mental status 3
• Manage seizures with benzodiazepines as first-line
• Monitor for hyperthermia and treat aggressively with cooling measures

Metabolic Complications:

• Check for rhabdomyolysis (elevated creatine kinase) 3
• Monitor renal function and provide aggressive IV hydration if rhabdomyolysis present
• Correct electrolyte abnormalities

Critical Pitfall

The evidence base for acute management is limited, with most recommendations based on symptomatic control rather than high-quality trials 3. However, the sympathomimetic toxidrome requires aggressive management to prevent progression to life-threatening complications.

Long-Term Treatment of Methamphetamine Use Disorder

First-Line Psychosocial Interventions

Contingency Management (CM) - Standard of Care:

• CM represents the current standard of care and should be the primary treatment offered 1
• Provides tangible rewards for drug-free urine samples
• Very low certainty evidence suggests CM alone increases abstinence duration by 21.20 days (95% CI, 11.39 to 31.00) compared to placebo 5

Optimal Combination Approach:

• The combination of contingency management plus community reinforcement approach is the most efficacious treatment both short and long-term 6
• This combination was superior to CM alone, CBT alone, and 12-step programs 6
• CM combined with CBT may increase abstinence duration by 34.85 days (95% CI, 19.63 to 50.08) compared to placebo 5

Cognitive Behavioral Therapy:

• CBT combined with any treatment approach is effective 7
• However, CBT did not outperform other evidence-based modalities like motivational enhancement therapy when combined with pharmacotherapy 7
• Should be offered as part of comprehensive treatment but not as monotherapy

Structured Exercise Programs:

• Self-directed or professionally led exercise improves addiction-specific outcomes and comorbid conditions 4
• Should be routinely offered as adjunctive treatment

Pharmacotherapy Options (Off-Label)

The evidence for pharmacotherapy remains weak, with low certainty across most agents 5, 1. However, several options may be considered:

Quetiapine (Strongest Pharmacologic Evidence):

• Low certainty evidence suggests quetiapine may extend abstinence (RR 3.17,95% CI 1.24 to 8.07) 5
• May increase weekly proportion of negative urine samples by 32.17% (95% CI, 14.08 to 50.26) 5
• Consider for patients with comorbid psychiatric symptoms

Riluzole:

• Low certainty evidence for increased negative urine samples (MD 24.10,95% CI 5.54 to 42.66) 5
• Limited availability and cost may restrict use

Long-Acting Methylphenidate (Conditional Recommendation):

• 2024 ASAM/AAAP guideline includes conditional recommendation based on low-certainty evidence 1, 8
• Very low certainty evidence suggests methylphenidate alone increases negative urine samples by 10.24% (95% CI 3.49 to 16.99) 5
• When combined with matrix model: 23.55% increase (95% CI 7.64 to 39.46) 5
• Requires structured behavioral engagement framework for safe implementation 8
• Monitor using 5 domains: adherence, abstinence progress, attendance, alternative activities, and accessing support 8
• Schedule II status requires careful oversight and diversion risk assessment

Agents with Better Tolerability:

• Venlafaxine (RR 0.27,95% CI 0.08 to 0.90) and citicoline (RR 0.69,95% CI 0.49 to 0.99) show favorable tolerability profiles 5

Avoid:

• Do not prescribe sertraline due to serious adverse events 4
• Substitution attempts with dexamphetamine lack robust evidence 4

Treatment Algorithm

1. Initiate contingency management as foundation - this is non-negotiable as standard of care 1
2. Add community reinforcement approach when available for optimal outcomes 6
3. Incorporate CBT or other evidence-based psychotherapy 7, 1
4. Prescribe structured exercise program 4
5. Consider off-label pharmacotherapy only as adjunct to psychosocial interventions:
   • Quetiapine for patients with psychiatric comorbidity or sleep disturbance
   • Long-acting methylphenidate only with robust behavioral engagement monitoring 8
   • Venlafaxine or citicoline for better tolerability profiles

Critical Limitations and Real-World Considerations

The evidence base remains sparse with low to very low certainty for most interventions 5, 1. No intervention demonstrates moderate to high-certainty evidence for important patient outcomes 5. Clinical trials suffer from high dropout rates and small sample sizes 4.

In clinical practice, this means:

• Prioritize contingency management despite imperfect evidence - it's the best we have
• Combine multiple psychosocial approaches rather than relying on single modality
• Use pharmacotherapy cautiously and only as adjunct, not primary treatment
• Set realistic expectations with patients about modest effect sizes
• Focus on harm reduction when abstinence is not immediately achievable 1

The lasting neurobiological changes from chronic methamphetamine use require pharmacotherapies that support both treatment engagement and functional recovery, not just substitution 9. Current approaches modeled on opioid maintenance therapy have shown limited effectiveness 9.